- Home
- DSGN vs ARL Comparison
DSGN vs ARL Comparison
Compare DSGN & ARL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DSGN | ARL |
|---|---|---|
| Founded | 2017 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Building operators |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 853.8M | 256.7M |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DSGN | ARL |
|---|---|---|
| Price | $12.40 | $15.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.00 | N/A |
| AVG Volume (30 Days) | ★ 641.6K | 3.7K |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 206.59 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $50,014,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 5.70 |
| 52 Week Low | $5.28 | $12.42 |
| 52 Week High | $17.25 | $24.44 |
Technical Indicators
Market Signals| Indicator | DSGN | ARL |
|---|---|---|
| Relative Strength Index (RSI) | 40.33 | 48.60 |
| Support Level | $11.82 | $14.45 |
| Resistance Level | $13.54 | $15.85 |
| Average True Range (ATR) | 0.70 | 0.61 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 33.35 | 49.81 |
Price Performance
Historical ComparisonAbout DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.
About ARL American Realty Investors Inc.
American Realty Investors Inc is a fully integrated externally managed real estate company. The company operates high-quality multifamily and commercial properties throughout the Southern United States and also invests in mortgage notes receivable and in land that is either held for appreciation or development. It operates in two reportable segments: the acquisition, development, ownership and management of multifamily properties (Residential Segment) and the acquisition, ownership and management of commercial real estate properties (Commercial Segment). Maximum revenue is generated from its Residential segment, which includes the rental of apartments and other tenants.